SCHEMBL718037

SCHEMBL718037

CC(C)(C)C(NC(=O)O)c1cc2cccc(Cl)c2nc1N1CCNC(=O)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
SOS1 Q07889 1/20 0.34
PIN1 Q13526 1/20 0.33
PRKCH P24723 1/20 0.32
PRKCE Q02156 1/20 0.32
KMT2A Q03164 1/20 0.32
ADRA2A P08913 1/20 0.32
PTGFR P43088 1/20 0.32
HTR3A P46098 1/20 0.32
TMEM97 Q5BJF2 1/20 0.32
XPO1 O14980 1/20 0.32
PIK3CD O00329 1/20 0.32
DPP4 P27487 1/20 0.32
DPP8 Q6V1X1 1/20 0.32
DPP9 Q86TI2 1/20 0.32
PIM1 P11309 1/20 0.31
PIM3 Q86V86 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL715530 0.91 PIK3CD (0.39) PDE4APDE4BPDE4CPDE4DSOS1
SCHEMBL8072 0.88 SOS1 (0.36) PDE4APDE4BPDE4CPDE4DSOS1
SCHEMBL17530837 0.80 ADRA2A (0.34) ADRA2APTGFRHTR3ATMEM97PIK3CD
SCHEMBL11673 0.80 PRKCH (0.37) PDE4APDE4BPDE4CPDE4DSOS1
SCHEMBL11674 0.80 PRKCH (0.37) PDE4APDE4BPDE4CPDE4DSOS1
SCHEMBL717883 0.77 SOS1 (0.36) PDE4APDE4BPDE4CPDE4DSOS1
SCHEMBL17530776 0.77 PIK3CD (0.47) PDE4APDE4BPDE4CPDE4DPIN1
SCHEMBL17530777 0.76 PRKCH (0.35) PDE4APDE4BPDE4CPDE4DPIN1
SCHEMBL10081 0.75 PIK3CD (0.42) PDE4APDE4BPDE4CPDE4DPIN1
SCHEMBL718038 0.75 PIK3CD (0.35) PDE4APDE4BPDE4CPDE4DPIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 PDE4A 1279/4885PDE4B 1577/4885PDE4C 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.